Table 5.

Comparison of clinical characteristics of apatinib and other novel antigens for relapsed and refractory NPC

Drug	Study	N	ORR	PFS	OS
Axitinib	Hui et al.	37	19%	5 months	10.4 months
Nivolumab	Ma et al. [20]	32	13%	3.5 months 3-month PFS, 64.2%	3-month OS, 87.5% OS was not reached
Pazopanib	Lim et al. [29]	33	6.1%	4.4 months	1-year OS, 32%
Interleukin-2	Chi et al. [30]	14	0	–	9 months
Adoptive T cell therapy	Smith et al. [22]	29	–	5.5 months	38.1 months